Johnson & Johnson will Pay $181 in Risperdal Settlement with 36 States

Defective Drugs

Johnson & Johnson subsidiary Janssen Pharmaceuticals will pay about $181 million to settle claims that it marketed the antipsychotic medication Risperdal for purposes for which it was not approved.

Thirty-six states and the District of Columbia charged Janssen with consumer fraud for allegedly marketing Risperdal to medical providers who treated Alzheimer’s and dementia patients. Risperdal was approved by the Food and Drug Administration (FDA) for the treatment of various forms of schizophrenia and bipolar disorder.

However, this dangerous pharmaceutical has also been used for the off-label treatment of Alzheimer’s disease, dementia and other conditions. While it is legal for physicians to prescribe medications for unapproved symptoms, drug manufacturers are not allowed to promote their medications for any uses other than approved conditions.

Risperdal has been associated with a number of severe medical problems, including an increased risk of death when administered to elderly patients who suffer from dementia-related psychosis. The drug has frequently been used in nursing homes to sedate elderly residents.

Legal disputes over the effects of Risperdal are ongoing. Federal prosecutors in March rejected a $1 billion settlement offer over Risperdal.

If you or a loved one was harmed by Risperdal or another dangerous product, a product liability attorney may be able to help you seek financial compensation for medical expenses, lost wages, pain and suffering, and other damages.

Please contact to locate an experienced product liability lawyer near you.